SCYNEXIS Inc. Common Stock (SCYX)
Stock · NASDAQ · Health Care
$3.67as of 10/16/2026
Price chart
Active signals
SCYX Signal Track Record
How signals performed across all stocks →What SCYX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | +1.0% | 52% | September 16, 2026 |
| Bollinger Band Breakdown | 22 | +1.4% | 59% | September 10, 2026 |
| Bollinger Band Breakout | 22 | -0.1% | 50% | August 4, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -0.9% | 43% | August 26, 2026 |
| Any 20-session window (baseline) | -2.4% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SCYX
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fu…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 18
- Website
- www.scynexis.com/
Fundamentals
- 1-day range
- $4.75$5.04
- Market cap
- $51.64M
- P/E (trailing)
- —
- P/E (forward)
- -2.06
- EPS (trailing)
- $-2.16
- Dividend yield
- —
- Beta
- 1.20
- Avg. volume
- 277.9K
- Dividend pay date
- July 17, 2020
How SCYNEXIS Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 4, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
SCYNEXIS Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SCYXSCYNEXIS Inc. Common Stock$3.67▼ 6.14%Market cap $51.64MP/E —$3.53$9.12
- RNXTRenovoRx Inc. Common Stock$1.14▼ 4.20%Market cap $51.86MP/E —$0.7006$2.59
- CPHIChina Pharma Holdings Inc. Common Stock$0.71▼ 2.74%Market cap $52.06MP/E —$0.3818$19.19
- SDEVStablecoin Development Corporation Common Stock$0.88▼ 13.73%Market cap $52.64MP/E 0.16$0.7809$99.75
- IBOImpact BioMedical Inc. Common Stock$2.68▼ 15.14%Market cap $48.61MP/E 61.61$4.67$10.47
- TCRTAlaunos Therapeutics Inc. Common Stock$2.63▲ 20.64%Market cap $48.60MP/E —$0.719$4.5
- INCRIntercure Ltd. Ordinary Shares$4.57▼ 1.72%Market cap $54.80MP/E —$253.3$2,740
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SCYX SCYNEXIS Inc. Common Stock | $51.64M | — | $3.67 | ▼ 6.14% | $3.53$9.12 |
| RNXT RenovoRx Inc. Common Stock | $51.86M | — | $1.14 | ▼ 4.20% | $0.7006$2.59 |
| CPHI China Pharma Holdings Inc. Common Stock | $52.06M | — | $0.71 | ▼ 2.74% | $0.3818$19.19 |
| SDEV Stablecoin Development Corporation Common Stock | $52.64M | 0.16 | $0.88 | ▼ 13.73% | $0.7809$99.75 |
| IBO Impact BioMedical Inc. Common Stock | $48.61M | 61.61 | $2.68 | ▼ 15.14% | $4.67$10.47 |
| TCRT Alaunos Therapeutics Inc. Common Stock | $48.60M | — | $2.63 | ▲ 20.64% | $0.719$4.5 |
| INCR Intercure Ltd. Ordinary Shares | $54.80M | — | $4.57 | ▼ 1.72% | $253.3$2,740 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SCYNEXIS Wins $214M BARDA Contract for SCY-247
SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.
SCYNEXIS Wins $214M BARDA Contract for SCY-247. SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.